Home  >  Research  >  Labs  >  Cancer Program  >  LIVER DISEASE AND CARCINOGENESIS

RESEARCH OVERVIEW

This Liver Disease and Carcinogenesis group focuses on the biology of the liver progenitor cell (LPC) called an “oval cell” which describes its shape. We envisage an enormous potential for LPCs as the vehicle for cell and gene therapy to treat liver disease. Liver progenitor cells are superior to other cells such as hepatocytes and embryonic (ESC) or adult stem cells (ASC) for many reasons. In particular, LPCs are robust and simple to freeze and store, they can then be thawed and grown by in vitro culture when required. They are more versatile than hepatocytes as they are easily and rapidly differentiated into either hepatocytes or cholangiocytes (bile duct cells) when maintained under appropriate conditions. Most importantly, the LPC is developmentally close to the hepatocyte and the cholangiocyte, in contrast to the ESC or ASC, which will require many more steps and much coaxing to produce useful cells for liver therapy.

Our long-term vision is to hasten the day when human LPCs are used to treat liver disease, especially end-stage liver disease for which currently organ transplant is the only solution. A realistic expectation in the short term is to use LPCs to “bridge” patients by extending their survival and enhancing their chances of finding a suitable organ donor. A more ambitious and longer-term aim is to use these cells to circumvent the requirement for organ transplant. This may be possible with some liver diseases.

Professor Yeoh recently gave a lecture about the rising incidence of liver cancer. Liver cancer is the fastest growing cancer threat in Australia, since 1984 incidence and mortality rates have doubled in Australian men and women. Watch Professor Yeoh’s seminar below.

Professor George Yeoh

Professor George Yeoh

Liver Disease and Carcinogenesis

Read more

LATEST NEWS

Dr Ankur Sharma in front of MRI image at Harry Perkins Institute of Medical Research

New liver cancer blood test gets $2.5m research funding boost

Predicting relapse for one of the world's deadliest cancers. Perth cancer researchers are on track to improve the outcomes of patients with the most common type of primary liver cancer. Hepatocellular carcinoma (HCC) is one of the most aggressive cancer types. Patients typically suffer a high rate of treatment failures.…

Read More
people in lab coats inside a cancer laboratory

ACRF Centre for Advanced Cancer Genomics opens in Perth

Latest technology analyses WA cancer patient tumours. The Australian Cancer Research Foundation (ACRF) Centre for Advanced Cancer Genomics, housing the next generation DNA sequencing technology, was opened today at the Harry Perkins Institute of Medical Research by the Federal Member for Curtin, Ms Kate Chaney. ACRF CEO, Kerry Strydom, in…

Read More

Connecting scientists and donors a winning mix

Harry Perkins Institute wins 2023 Fundraising Team of the Year In the midst of the Golden Globes and the Oscars season, a small team in Perth who support medical research has won three sought-after fundraising gongs, including Australia’s 2023 Fundraising Team of the Year. The team from the Harry Perkins…

Read More

I'M LOOKING FOR

RESEARCH PROJECTS

TEAM MEMBERS

PUBLICATIONS